hVIVO (LON:HVO) Trading 11.9% Higher – Still a Buy?

Shares of hVIVO plc (LON:HVO) were up 11.9% on Friday . The company traded as high as GBX 7.50 and last traded at GBX 7.50. 4,541,654 shares were traded during mid-day trading, an increase of 59% from the average daily volume of 2,858,300 shares. The stock had previously closed at GBX 6.70.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on HVO shares. Shore Capital Group reissued a “buy” rating on shares of hVIVO in a research note on Wednesday, April 22nd. Stifel Nicolaus restated a “hold” rating and set a GBX 10 price objective on shares of hVIVO in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of GBX 15.

hVIVO Trading Up 11.9%

The company has a market cap of £51.63 million, a price-to-earnings ratio of -8.62 and a beta of 1.71. The company has a current ratio of 1.63, a quick ratio of 1.16 and a debt-to-equity ratio of 38.75. The business’s 50 day moving average price is GBX 7.57 and its 200-day moving average price is GBX 7.43.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.